This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lteif, A. N.
Right arrow Articles by Zimmerman, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lteif, A. N.
Right arrow Articles by Zimmerman, D.
Related Collections
Right arrow Nutrition & Metabolism
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

PEDIATRICS Vol. 102 No. 4 October 1998, pp. 990-993

EXPERIENCE AND REASON:
Bisphosphonates for Treatment of Childhood Hypercalcemia

Received Feb 17, 1998; accepted Apr 6, 1998.

Aida N. Lteif and Donald Zimmerman

Department of Pediatrics and Adolescent Medicine Mayo Clinic Rochester, MN 55905

Most clinicians only have a limited experience in treating childhood hypercalcemia with bisphosphonates. We report our experience in the use of intravenous and oral bisphosphonates in a 5-year-old with hypercalcemia secondary to acute lymphocytic leukemia, a 16-year-old with immobilization hypercalcemia, and a 14-year-old with chronic hypercalcemia of unknown cause. Single infusions of 0.5 mg/kg and 1 mg/kg of intravenous pamidronate were administered over 4 hours. No adverse reactions were observed except for hypocalcemia. A dose between 10 and 20 mg of oral alendronate was successfully used to maintain normocalcemia in the patient with chronic hypercalcemia. In our experience, the administration of bisphosphonates has enabled us to achieve normocalcemia in all cases, and in all cases there were no significant side effects. Long-term potential side effects from their use in children during the active phase of growth remain unknown.

 Key words:  hypercalcemia, pamidronate, alendronate, side effects.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
R. A. Cahill, D. Wenkert, S. A. Perlman, A. Steele, S. P. Coburn, W. H. McAlister, S. Mumm, and M. P. Whyte
Infantile Hypophosphatasia: Transplantation Therapy Trial Using Bone Fragments and Cultured Osteoblasts
J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2923 - 2930.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
N J Shaw and N J Bishop
Bisphosphonate treatment of bone disease
Arch. Dis. Child., May 1, 2005; 90(5): 494 - 499.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
L. Qadan, M. Al-Quaimi, and A. Ahmad
Slipped Capital Femoral Epiphysis Associated with Primary Hyperparathyroidism and Severe Hypercalcemia
Clinical Pediatrics, June 1, 2003; 42(5): 439 - 441.
[PDF]

Home page
 PediatricsHome page
A. Bereket and T. Erdogan
Oral Bisphosphonate Therapy for Vitamin D Intoxication of the Infant
Pediatrics, April 1, 2003; 111(4): 899 - 901.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
T. Ohnishi, E. Takeda, S. Yogita, H. Miyake, T. Kinoshita, Y. Terashima, T. Matsumoto, and S. Tashiro
Effects of Alendronate on Bone Metastases and Hypercalcemia After Surgery for Hepatocellular Carcinoma
Jpn. J. Clin. Oncol., September 1, 2000; 30(9): 410 - 413.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
T. Srivastava and U. S. Alon
Bisphosphonates: From Grandparents to Grandchildren
Clinical Pediatrics, November 1, 1999; 38(12): 687 - 702.
[Abstract] [PDF]